Liquid Biopsy Market Size, Growth Strategies 2022-28
The global liquid biopsy market size was valued at USD 4.4 billion in 2021 and is expected to reach a value of USD x million by 2028, growing at a CAGR of 18.2% during the forecast period 2022 to 2028. Liquid biopsy is a non-invasive and straightforward alternative to ‘conventional' or surgical biopsies, and it entails the collection and examination of non-solid biological matter, usually blood. Medical practitioners can use liquid biopsies to learn about various characteristics of a tumor from a patient's blood sample. Medical practitioners can use the liquid biopsy to figure out which therapies are best for the patient. In the event of patients whose tissue cannot be biopsied or as an addendum to thoroughly analyses medication response, liquid biopsies are a helpful substitute to surgical biopsies. These procedures also allow medical practitioners to acquire repeated samples during the primary treatment (which is not possible with a Tumor biopsy) in order to evaluate the tumor's development and medication sensitivity in the patient. View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/liquid-biopsy-market/
The global liquid biopsy market segmentation: 1) By-Products and Services: Instruments, Reagents, and Services & Software 2) By Biomarker Type: Circulating Tumor Cells (CTC), Circulating Tumor DNA (ctDNA), Exosomes, and Others 3) By Sample Type: Blood Samples, Urine Samples, and Other Biofluid Samples 4) By Application: Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Leukemia, Lung Cancer, Prostate Cancer, and Other Cancers 5) By Analysis Method: Multigene – parallel Analysis and Single Gene Analysis (PCR Microarrays) 6) By End-User: Hospitals, Diagnostic Laboratories, and Academic and Research Institutes.
Liquid biopsy is a common and safe method used during the cancer diagnostic process. Early cancer diagnosis and screening, characterization of new lesions, and pharmacological and therapeutic target attributions for cancer therapy are some of the significant benefits of liquid biopsies, which improve the safety and effectiveness of cancer treatment, these factors on the other hand is expected to fuel the Liquid Biopsy Market in the coming years. The benefit of liquid biopsy versus solid tumor biopsy are becoming increasingly apparent as cancer rates rise. With the rising demand for non-invasive treatments, governmental and private funding for researchers in the context of liquid biopsy is expanding, which is further is expected to boost the market in the coming years.
Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=17392
In 2021, Asia-Pacific had the highest market share, while North America had the second largest. Because it has evolved as a significant manufacturer and supplier of Liquid Biopsy to the worldwide, the Asia Pacific area is regarded to be the largest production hub for Liquid Biopsy.
The liquid biopsy market key players are Biocept Inc. (U.S), Bio-Rad Laboratories Inc. (U.S), Fraunhofer-Gesellschaft (Germany), Guardant Health, Inc. (U.S), Janssen Diagnostics, LLC (U.S), MDxHealth SA (U.S), Myriad Genetics (U.S), QIAGEN (Netherlands), RainDance Technologies, Inc. (U.S), Roche (Switzerland), Trovagene Inc. (U.S)
About Precision Business Insights: We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.
Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.
Contact: Mr. Satya Precision Business Insights | Toll Free: +1 866 598 1553 Email: sales@precisionbusinessinsights.com Kemp House, 152 – 160 City Road, London EC1V 2NX Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747